Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer.
Journal: Journal for immunotherapy of cancer
Published: June 21, 2022
FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: May 31, 2019
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
Journal: The New England journal of medicine
Published: December 06, 2018
Effect of OATP1B1/1B3 Inhibitor GDC-0810 on the Pharmacokinetics of Pravastatin and Coproporphyrin I/III in Healthy Female Subjects.
Journal: Journal of clinical pharmacology
Published: January 22, 2018
Concordance between plasma-based and tissue-based next-generation sequencing in LOTUS.
Journal: The Lancet. Oncology
Published: September 25, 2017
A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer.
Journal: Breast cancer research : BCR
Published: September 15, 2017
Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: March 02, 2016
KIF14 promotes AKT phosphorylation and contributes to chemoresistance in triple-negative breast cancer.
Journal: Neoplasia (New York, N.Y.)
Published: December 05, 2013
Receptor-interacting protein kinase 2 promotes triple-negative breast cancer cell migration and invasion via activation of nuclear factor-kappaB and c-Jun N-terminal kinase pathways.
Journal: Breast cancer research : BCR
Published: June 25, 2013
A targeted RNAi screen of the breast cancer genome identifies KIF14 and TLN1 as genes that modulate docetaxel chemosensitivity in triple-negative breast cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 13, 2013
Showing 1-12 of 12
Last Updated: 09/26/2026